U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858969) titled 'Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer' on Feb. 28.
Brief Summary: This phase II, open-label, dose-escalation study aims to (1) assess the safety and tolerability of chidamide in combination with PD-1 inhibitor, bevacizumab, and XELOX as first-line therapy for treatment-naive metastatic colorectal cancer patients, (2) establish the recommended phase II dose (RP2D) of the combination regimen, and (3) obtain preliminary efficacy data including objective response rate (ORR) and progression-free survival (PFS).
Study Start Date: April 09
Study Type: INTERVENTIONAL
Conditi...